Characterization of prostate cancer using T2 mapping at 3 T: A multi-scanner study

Rationale and objectivesTo assess the prostate T2 value as a predictor of malignancy on two different 3 T scanners.Patients and methodsEighty-three pre-prostatectomy multiparametric MRIs were retrospectively evaluated [67 obtained on a General Electric MRI (scanner 1) and 16 on a Philips MRI (scanner 2)]. After correlation with prostatectomy specimens, readers measured the T2 value of regions-of-interest categorized as “cancers”, “false positive lesions”, or “normal tissue”.ResultsOn scanner 1, in PZ, cancers had significantly lower T2 values than false positive lesions (P = 0.02) and normal tissue (P = 2 × 10−9). Gleason ≥ 6 cancers had similar T2 values than false positive lesions and significantly higher T2 values than Gleason ≥ 7 cancers (P = 0.009). T2 values corresponding to a 25% and 75% risk of Gleason ≥ 7 malignancy were respectively 132 ms (95% CI: 129–135 ms) and 77 ms (95% CI: 74–81 ms). In TZ, cancers had significantly lower T2 values than normal tissue (P = 0.008), but not than false positive findings. Mean T2 values measured on scanner 2 were not significantly different than those measured on scanner 1 for all tissue classes.ConclusionAll tested tissue classes had similar mean T2 values on both scanners. In PZ, the T2 value was a significant predictor of Gleason ≥ 7 cancers.